Immunogenetics of systemic lupus erythematosus: A comprehensive review

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 125-136

  Ghodke Puranik, Yogita ^a   Niewold, Timothy B ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune diseases; Genetics; Interferon; Systemic lupus erythematosus

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AICARDI GOUTIERES SYNDROME TYPE 5 PROTEIN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE SPECIFIC TYROSINE KINASE; DEOXYRIBONUCLEASE I; DEOXYRIBONUCLEASE III; HLA ANTIGEN; IKAROS TRANSCRIPTION FACTOR; IMMUNOGLOBULIN LIKE TRANSCRIPT 3 RECEPTOR; INTERFERON; INTERFERON REGULATORY FACTOR; MICRORNA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOPONTIN; PROTEIN KINASE C DELTA; STAT4 PROTEIN; STIMULATOR OF INTERFERON GENE PROTEIN; TRANSCRIPTION FACTOR ETS 1; TUMOR NECROSIS FACTOR ALPHA INDUCIBLE PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA INDUCIBLE PROTEIN 3 INTERACTING PROTEIN 1; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; CANCER INHIBITION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLEMENT DEFICIENCY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; IMMUNOGENETICS; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MONOGENIC DISORDER; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; GENE LOCUS; GENETIC EPIGENESIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; MULTIFACTORIAL INHERITANCE; OPEN READING FRAME; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; EPIGENESIS, GENETIC; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGENETICS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIFACTORIAL INHERITANCE; OPEN READING FRAMES; POLYMORPHISM, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION;

EID: 84946481488     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.08.004     Document Type: Review

References (157)

1. Lopez P., Mozo L., Gutierrez C., Suarez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 2003, 12:860-865.
2. Weckerle C.E., Niewold T.B. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin. Rev. Allergy Immunol. 2011, 40:42-49.
3. Harley J.B., Kelly J.A., Kaufman K.M. Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol. 2006, 28:119-130.
4. Ko K., Koldobskaya Y., Rosenzweig E., Niewold T.B. Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients. Front. Immunol. 2013, 4:309.
5. Sanchez E., Comeau M.E., Freedman B.I., Kelly J.A., Kaufman K.M., Langefeld C.D., et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 2011, 63:3493-3501.
6. Ko K., Franek B.S., Marion M., Kaufman K.M., Langefeld C.D., Harley J.B., et al. Genetic ancestry, serum interferon-alpha activity, and autoantibodies in systemic lupus erythematosus. J. Rheumatol. 2012, 39:1238-1240.
7. Sharma S., Jin Z., Rosenzweig E., Rao S., Ko K., Niewold T.B. Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J. Autoimmun. 2015, 60:51-58.
8. Alarcon-Segovia D., Alarcon-Riquelme M.E., Cardiel M.H., Caeiro F., Massardo L., Villa A.R., et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005, 52:1138-1147.
9. Deapen D., Escalante A., Weinrib L., Horwitz D., Bachman B., Roy-Burman P., et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35:311-318.
10. Block S.R., Winfield J.B., Lockshin M.D., D'Angelo W.A., Christian C.L. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am. J. Med. 1975, 59:533-552.
11. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8:492-502.
12. Deng Y., Tsao B.P. Advances in lupus genetics and epigenetics. Curr. Opin. Rheumatol. 2014, 26:482-492.
13. Ghodke-Puranik Y., Niewold T.B. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int. J. Clin. Rheumatol. 2013, 8.
14. Crow M.K. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2014, 26:467-474.
15. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
16. Niewold T.B. Interferon alpha as a primary pathogenic factor in human lupus. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 2011, 31:887-892.
17. Fitzgerald-Bocarsly P., Dai J., Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008, 19:3-19.
18. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 1979, 301:5-8.
19. Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin. Rheumatol. 2005, 24:178-181.
20. Ronnblom L.E., Alm G.V., Oberg K.E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 1990, 227:207-210.
21. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 2009, 182:34-38.
22. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
23. Kariuki S.N., Niewold T.B. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl. Res. 2010, 155:109-117.
24. Kariuki S.N., Franek B.S., Kumar A.A., Arrington J., Mikolaitis R.A., Utset T.O., et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:R151.
25. Kariuki S.N., Ghodke-Puranik Y., Dorschner J.M., Chrabot B.S., Kelly J.A., Tsao B.P., et al. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun. 2015, 16:15-23.
26. Jensen M.A., Patterson K.C., Kumar A.A., Kumabe M., Franek B.S., Niewold T.B. Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. Ann. Rheum. Dis. 2013, 72:596-601.
27. Pothlichet J., Niewold T.B., Vitour D., Solhonne B., Crow M.K., Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med. 2011, 3:142-152.
28. Harley I.T., Niewold T.B., Stormont R.M., Kaufman K.M., Glenn S.B., Franek B.S., et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010.
29. Fernando M.M., Stevens C.R., Walsh E.C., De Jager P.L., Goyette P., Plenge R.M., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008, 4:e1000024.
30. Connolly J.J., Hakonarson H. Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing. J. Biomed. Biotechnol. 2012, 2012:798924.
31. Yang W., Shen N., Ye D.Q., Liu Q., Zhang Y., Qian X.X., et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 2010, 6:e1000841.
32. Gateva V., Sandling J.K., Hom G., Taylor K.E., Chung S.A., Sun X., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 2009, 41:1228-1233.
33. Chung S.A., Taylor K.E., Graham R.R., Nititham J., Lee A.T., Ortmann W.A., et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 2011, 7:e1001323.
34. Morris D.L., Fernando M.M., Taylor K.E., Chung S.A., Nititham J., Alarcon-Riquelme M.E., et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun. 2014, 15:210-217.
35. Jiang C., Deshmukh U.S., Gaskin F., Bagavant H., Hanson J., David C.S., et al. Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens. J. Immunol. 2010, 184:1085-1091.
36. Fernando M.M., Stevens C.R., Sabeti P.C., Walsh E.C., McWhinnie A.J., Shah A., et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet. 2007, 3:e192.
37. Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., Moser K.L., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 2008, 40:204-210.
38. Jensen M.A., Niewold T.B. Interferon regulatory factors: critical mediators of human lupus. Transl. Res. 2015, 165:283-295.
39. Zhao G.N., Jiang D.S., Li H. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim. Biophys. Acta 2015, 1852:365-378.
40. Cham C.M., Ko K., Niewold T.B. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 2012:780436.
41. Graham R.R., Kyogoku C., Sigurdsson S., Vlasova I.A., Davies L.R., Baechler E.C., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6758-6763.
42. Niewold T.B., Kelly J.A., Kariuki S.N., Franek B.S., Kumar A.A., Kaufman K.M., et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 2012, 71:463-468.
43. Cherian T.S., Kariuki S.N., Franek B.S., Buyon J.P., Clancy R.M., Niewold T.B. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 2012, 64:3383-3387.
44. Suarez-Gestal M., Calaza M., Endreffy E., Pullmann R., Ordi-Ros J., Sebastiani G.D., et al. Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res. Ther. 2009, 11:R69.
45. Fu Q., Zhao J., Qian X., Wong J.L., Kaufman K.M., Yu C.Y., et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:749-754.
46. Salloum R., Franek B.S., Kariuki S.N., Rhee L., Mikolaitis R.A., Jolly M., et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010, 62:553-561.
47. Lee M.N., Ye C., Villani A.C., Raj T., Li W., Eisenhaure T.M., et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 2014, 343:1246980.
48. Tsujimura H., Tamura T., Kong H.J., Nishiyama A., Ishii K.J., Klinman D.M., et al. Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J. Immunol. 2004, 172:6820-6827.
49. Hambleton S., Salem S., Bustamante J., Bigley V., Boisson-Dupuis S., Azevedo J., et al. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 2011, 365:127-138.
50. Lessard C.J., Adrianto I., Ice J.A., Wiley G.B., Kelly J.A., Glenn S.B., et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 2012, 90:648-660.
51. De Jager P.L., Jia X., Wang J., de Bakker P.I., Ottoboni L., Aggarwal N.T., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 2009, 41:776-782.
52. Chrabot B.S., Kariuki S.N., Zervou M.I., Feng X., Arrington J., Jolly M., et al. Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 2013, 14:471-478.
53. Korman B.D., Kastner D.L., Gregersen P.K., Remmers E.F. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr. Allergy Asthma Rep. 2008, 8:398-403.
54. Zheng J., Yin J., Huang R., Petersen F., Yu X. Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody. Hum. Immunol. 2013, 74:986-992.
55. Robinson T., Kariuki S.N., Franek B.S., Kumabe M., Kumar A.A., Badaracco M., et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J. Immunol. 2011, 187:1298-1303.
56. Molineros J.E., Maiti A.K., Sun C., Looger L.L., Han S., Kim-Howard X., et al. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet. 2013, 9:e1003222.
57. Katagiri Y., Mori K., Hara T., Tanaka K., Murakami M., Uede T. Functional analysis of the osteopontin molecule. Ann. N. Y. Acad. Sci. 1995, 760:371-374.
58. Forton A.C., Petri M.A., Goldman D., Sullivan K.E. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum. Mutat. 2002, 19:459.
59. Kariuki S.N., Moore J.G., Kirou K.A., Crow M.K., Utset T.O., Niewold T.B. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 2009, 10:487-494.
60. Cao W., Liu Y.J. Opn: key regulator of pDC interferon production. Nat. Immunol. 2006, 7:441-443.
61. Pettigrew H.D., Teuber S.S., Gershwin M.E. Clinical significance of complement deficiencies. Ann. N. Y. Acad. Sci. 2009, 1173:108-123.
62. Slingsby J.H., Norsworthy P., Pearce G., Vaishnaw A.K., Issler H., Morley B.J., et al. Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum. 1996, 39:663-670.
63. Provost T.T., Arnett F.C., Reichlin M. Homozygous C2 deficiency, lupus erythematosus, and anti-Ro (SSA) antibodies. Arthritis Rheum. 1983, 26:1279-1282.
64. Fielder A.H., Walport M.J., Batchelor J.R., Rynes R.I., Black C.M., Dodi I.A., et al. Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br. Med. J. Clin. Res. Ed. 1983, 286:425-428.
65. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
66. Davies E.J., Steers G., Ollier W.E., Grennan D.M., Cooper R.G., Hay E.M., et al. Relative contributions of HLA-DQA and complement C4A loci in determining susceptibility to systemic lupus erythematosus. Br. J. Rheumatol. 1995, 34:221-225.
67. Munoz L.E., van Bavel C., Franz S., Berden J., Herrmann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375.
68. Ren Y., Tang J., Mok M.Y., Chan A.W., Wu A., Lau C.S. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 2003, 48:2888-2897.
69. Fukuyama H., Adachi M., Suematsu S., Miwa K., Suda T., Yoshida N., et al. Requirement of Fas expression in B cells for tolerance induction. Eur. J. Immunol. 2002, 32:223-230.
70. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
71. Shah S., Wu E., Rao V.K., Tarrant T.K. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr. Allergy Asthma Rep. 2014, 14:462.
72. Xiang N., Li X.M., Wang G.S., Tao J.H., Li X.P. Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol. Biol. Rep. 2013, 40:407-415.
73. Budagyan V.M., Bulanova E.G., Sharova N.I., Nikonova M.F., Stanislav M.L., Yarylin A.A. The resistance of activated T-cells from SLE patients to apoptosis induced by human thymic stromal cells. Immunol. Lett. 1998, 60:1-5.
74. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 2003, 170:132-138.
75. Pinti M., Troiano L., Nasi M., Moretti L., Monterastelli E., Mazzacani A., et al. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ. 2002, 9:431-438.
76. Moudi B., Salimi S., Farajian Mashhadi F., Sandoughi M., Zakeri Z. Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. Sci. World J. 2013, 2013:176741.
77. Sallai K., Nagy E., Derfalvy B., Muzes G., Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin. Diagn. Lab. Immunol. 2005, 12:56-59.
78. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 2000, 25:177-181.
79. Yasutomo K., Horiuchi T., Kagami S., Tsukamoto H., Hashimura C., Urushihara M., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 2001, 28:313-314.
80. Al-Mayouf S.M., Sunker A., Abdwani R., Abrawi S.A., Almurshedi F., Alhashmi N., et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 2011, 43:1186-1188.
81. Belot A., Kasher P.R., Trotter E.W., Foray A.P., Debaud A.L., Rice G.I., et al. Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013, 65:2161-2171.
82. Steinberg S.F. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem. J. 2004, 384:449-459.
83. Mecklenbrauker I., Saijo K., Zheng N.Y., Leitges M., Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 2002, 416:860-865.
84. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
85. Ramantani G., Kohlhase J., Hertzberg C., Innes A.M., Engel K., Hunger S., et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum. 2010, 62:1469-1477.
86. Namjou B., Kothari P.H., Kelly J.A., Glenn S.B., Ojwang J.O., Adler A., et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011, 12:270-279.
87. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 2007, 39:1065-1067.
88. Burdette D.L., Vance R.E. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 2013, 14:19-26.
89. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
90. Lo M., Tsokos G. Monogenic lupus. Int. J. Clin. Rheumatol. 2014, 9:543-546.
91. Jeremiah N., Neven B., Gentili M., Callebaut I., Maschalidi S., Stolzenberg M.C., et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Investig. 2014, 124:5516-5520.
92. Liu Y., Jesus A.A., Marrero B., Yang D., Ramsey S.E., Montealegre Sanchez G.A., et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371:507-518.
93. Jin L., Xu L.G., Yang I.V., Davidson E.J., Schwartz D.A., Wurfel M.M., et al. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun. 2011, 12:263-269.
94. Beloglazova N., Flick R., Tchigvintsev A., Brown G., Popovic A., Nocek B., et al. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J. Biol. Chem. 2013, 288:8101-8110.
95. Xin B., Jones S., Puffenberger E.G., Hinze C., Bright A., Tan H., et al. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5372-5377.
96. Chahwan C., Chahwan R. Aicardi-Goutieres syndrome: from patients to genes and beyond. Clin. Genet. 2012, 81:413-420.
97. Li N., Zhang W., Cao X. Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells. Immunol. Lett. 2000, 74:221-224.
98. Berger A., Sommer A.F., Zwarg J., Hamdorf M., Welzel K., Esly N., et al. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 2011, 7:e1002425.
99. Rice G.I., Bond J., Asipu A., Brunette R.L., Manfield I.W., Carr I.M., et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 2009, 41:829-832.
100. Welbourn S., Miyagi E., White T.E., Diaz-Griffero F., Strebel K. Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirology 2012, 9:86.
101. Crow Y.J., Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 2009, 18:R130-R136.
102. Briggs T.A., Rice G.I., Daly S., Urquhart J., Gornall H., Bader-Meunier B., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 2011, 43:127-131.
103. Lausch E., Janecke A., Bros M., Trojandt S., Alanay Y., De Laet C., et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat. Genet. 2011, 43:132-137.
104. Andersson G., Ek-Rylander B., Hollberg K., Ljusberg-Sjolander J., Lang P., Norgard M., et al. TRACP as an osteopontin phosphatase. J. Bone Min. Res. 2003, 18:1912-1915.
105. Han S., Guthridge J.M., Harley I.T., Sestak A.L., Kim-Howard X., Kaufman K.M., et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One 2008, 3:e0001757.
106. Beyaert R., Heyninck K., Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem. Pharmacol. 2000, 60:1143-1151.
107. Flesher D.L., Sun X., Behrens T.W., Graham R.R., Criswell L.A. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2010, 6:461-479.
108. Bates J.S., Lessard C.J., Leon J.M., Nguyen T., Battiest L.J., Rodgers J., et al. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. 2009, 10:470-477.
109. Graham R.R., Cotsapas C., Davies L., Hackett R., Lessard C.J., Leon J.M., et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 2008, 40:1059-1061.
110. Musone S.L., Taylor K.E., Lu T.T., Nititham J., Ferreira R.C., Ortmann W., et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 2008, 40:1062-1064.
111. Lodolce J.P., Kolodziej L.E., Rhee L., Kariuki S.N., Franek B.S., McGreal N.M., et al. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J. Immunol. 2010, 184:7001-7009.
112. Adrianto I., Wen F., Templeton A., Wiley G., King J.B., Lessard C.J., et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 2011, 43:253-258.
113. Wang S., Wen F., Wiley G.B., Kinter M.T., Gaffney P.M. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet. 2013, 9:e1003750.
114. Han J.W., Zheng H.F., Cui Y., Sun L.D., Ye D.Q., Hu Z., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 2009, 41:1234-1237.
115. Adrianto I., Wang S., Wiley G.B., Lessard C.J., Kelly J.A., Adler A.J., et al. Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 2012, 64:3695-3705.
116. Caster D.J., Korte E.A., Nanda S.K., McLeish K.R., Oliver R.K., G'Sell R.T., et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J. Am. Soc. Nephrol. JASN 2013, 24:1743-1754.
117. Hom G., Graham R.R., Modrek B., Taylor K.E., Ortmann W., Garnier S., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 2008, 358:900-909.
118. Guthridge J.M., Lu R., Sun H., Sun C., Wiley G.B., Dominguez N., et al. Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am. J. Hum. Genet. 2014, 94:586-598.
119. Maier H., Colbert J., Fitzsimmons D., Clark D.R., Hagman J. Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. Mol. Cell Biol. 2003, 23:1946-1960.
120. Moisan J., Grenningloh R., Bettelli E., Oukka M., Ho I.C. Ets-1 is a negative regulator of Th17 differentiation. J. Exp. Med. 2007, 204:2825-2835.
121. Wang C., Ahlford A., Jarvinen T.M., Nordmark G., Eloranta M.L., Gunnarsson I., et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur. J. Hum. Genet. 2013, 21:994-999.
122. Wang D., John S.A., Clements J.L., Percy D.H., Barton K.P., Garrett-Sinha L.A. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int. Immunol. 2005, 17:1179-1191.
123. Lu X., Zoller E.E., Weirauch M.T., Wu Z., Namjou B., Williams A.H., et al. Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. Am. J. Hum. Genet. 2015, 96:731-739.
124. Wojcik H., Griffiths E., Staggs S., Hagman J., Winandy S. Expression of a non-DNA-binding Ikaros isoform exclusively in B cells leads to autoimmunity but not leukemogenesis. Eur. J. Immunol. 2007, 37:1022-1032.
125. Hu W., Sun L., Gao J., Li Y., Wang P., Cheng Y., et al. Down-regulated expression of IKZF1 mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Rheumatol. Int. 2011, 31:819-822.
126. Westra H.J., Peters M.J., Esko T., Yaghootkar H., Schurmann C., Kettunen J., et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 2013, 45:1238-1243.
127. Cohen S., Dadi H., Shaoul E., Sharfe N., Roifman C.M. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase. Lymph. Blood 1999, 93:2013-2024.
128. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., Song G.G., Nath S.K., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatol. Oxf. 2007, 46:49-56.
129. Orru V., Tsai S.J., Rueda B., Fiorillo E., Stanford S.M., Dasgupta J., et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum. Mol. Genet. 2009, 18:569-579.
130. Stanford S.M., Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat. Rev. Rheumatol. 2014, 10:602-611.
131. Kariuki S.N., Crow M.K., Niewold T.B. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum. 2008, 58:2818-2823.
132. Wang Y., Shaked I., Stanford S.M., Zhou W., Curtsinger J.M., Mikulski Z., et al. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 2013, 39:111-122.
133. Habib T., Funk A., Rieck M., Brahmandam A., Dai X., Panigrahi A.K., et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 2012, 188:487-496.
134. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Investig. 2011, 121:3635-3644.
135. Cella M., Dohring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J. Exp. Med. 1997, 185:1743-1751.
136. Jensen M.A., Yanowitch R.N., Reder A.T., White D.M., Arnason B.G. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult. Scler. 2010, 16:30-38.
137. Javierre B.M., Fernandez A.F., Richter J., Al-Shahrour F., Martin-Subero J.I., Rodriguez-Ubreva J., et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010, 20:170-179.
138. Hedrich C.M., Tsokos G.C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol. Med. 2011, 17:714-724.
139. Javierre B.M., Richardson B. A new epigenetic challenge: systemic lupus erythematosus. Adv. Exp. Med. Biol. 2011, 711:117-136.
140. Absher D.M., Li X., Waite L.L., Gibson A., Roberts K., Edberg J., et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 2013, 9:e1003678.
141. Coit P., Jeffries M., Altorok N., Dozmorov M.G., Koelsch K.A., Wren J.D., et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 2013, 43:78-84.
142. Koelsch K.A., Webb R., Jeffries M., Dozmorov M.G., Frank M.B., Guthridge J.M., et al. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J. Autoimmun. 2013, 41:168-174.
143. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
144. Zhang Z., Song L., Maurer K., Petri M.A., Sullivan K.E. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 2010, 11:124-133.
145. Dozmorov M.G., Wren J.D., Alarcon-Riquelme M.E. Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 2014, 9:276-285.
146. Trynka G., Sandor C., Han B., Xu H., Stranger B.E., Liu X.S., et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat. Genet. 2013, 45:124-130.
147. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
148. Qu B., Shen N. miRNAs in the Pathogenesis of Systemic Lupus Erythematosus. Int. J. Mol. Sci. 2015, 16:9557-9572.
149. Pauley K.M., Cha S., Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. J. Autoimmun. 2009, 32:189-194.
150. Hou J., Wang P., Lin L., Liu X., Ma F., An H., et al. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 2009, 183:2150-2158.
151. Tang Y., Luo X., Cui H., Ni X., Yuan M., Guo Y., et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60:1065-1075.
152. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.
153. Zhou H., Huang X., Cui H., Luo X., Tang Y., Chen S., et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010, 116:5885-5894.
154. Carlsen A.L., Schetter A.J., Nielsen C.T., Lood C., Knudsen S., Voss A., et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 2013, 65:1324-1334.
155. Luo X., Yang W., Ye D.Q., Cui H., Zhang Y., Hirankarn N., et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011, 7:e1002128.
156. Hikami K., Kawasaki A., Ito I., Koga M., Ito S., Hayashi T., et al. Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:755-763.
157. Deng Y., Zhao J., Sakurai D., Kaufman K.M., Edberg J.C., Kimberly R.P., et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 2013, 9:e1003336.